Ovid Therapeutics Inc.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 18, 2026 | Before market open | $700.00K | $0.06 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 12, 2025 | Before market open | – | $-0.17 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | Before market open | – | $-0.14 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 11, 2025 | Before market open | $76.00K | $-0.13 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 14, 2024 | Before market open | – | $-0.17 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 8, 2024 | Before market open | – | $-0.22 | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 3, 2023 | Before market open | – | $-0.16 | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 4, 2023 | Before market open | $75.00K | $-0.18 | – |
| Q1 FY2023 Ended Mar 31, 2023 | May 5, 2023 | Before market open | – | – | – |
| Q4 FY2022 Ended Dec 31, 2022 | Mar 13, 2023 | Before market open | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 8, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 9, 2022 | Before market open | – | – | – |
Press releases
Announcements Ovid Therapeutics filed with the SEC
Ovid Therapeutics Announces New OV329 Data and Indication Expansion,
Material agreement · Results of operations · Unregistered share sale · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride
Other events · EX-99.1 to Form 8-K
Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Ovid announces positive topline results for the next-generation GABA-
Material agreement · Unregistered share sale · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Other events · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Business Updates and First Quarter 2025 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Reports on Takeda’s Announcement of Phase 3 Topline Study Results for Soticlestat
Regulation FD disclosure · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Business Updates and First Quarter 2024 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026
Material agreement · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
OVID R&D DAY OCTOBER 2, 2023
Other events · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors
Other events · EX-99 to Form 8-K
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Third Quarter 2022 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
Material agreement · Unregistered share sale · Regulation FD disclosure · EX-99.1 to Form 8-K
Ovid Therapeutics Reports Third Quarter 2021 Business Update,
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K